NASDAQ$TRML

Tourmaline Bio Inc · Q2 2025 earnings

Q2 2025 earnings · · Before market open · Investor relations

Briefing

Tourmaline Bio reported Q2 2025, net loss of $23.1M.

For Q2 2025, Tourmaline Bio reported a net loss of $23.1M. The filing discusses segment trends, liquidity, and management outlook for upcoming periods.

  • Net loss $23.1M.
  • Tourmaline Bio highlights operating priorities and capital allocation.
  • Tourmaline Bio highlights operating priorities and capital allocation.

Headline financials

Total Revenue

$0.00

Previous: $87K-100.0%
EPS (adj)

-$0.90

Previous: -$0.68-32.4%
R&D Expenses

$19.6M

Previous: $15.7M+24.8%
G&A Expenses

$6.34M

Previous: $6.24M+1.7%
Total Operating Expenses

$26M

Previous: $22M+18.2%
Other Income, Net

$2.88M

Previous: $4.48M-35.7%
Weighted Avg Shares

25.8M

No prior period
Working Capital

$239M

No prior period
Stockholders’ Equity

$259M

No prior period
Capital Expenditures

-$16K

Previous: $0.00
Net Income

-$23.1M

Previous: -$17.5M-32.1%
Operating Income

-$26M

Previous: -$22M-18.2%

Revenue & EPS history

Tourmaline Bio · Revenue · Quarterly

$0

Q2 2025-100%vs Q2 2024

Forward guidance

The release discusses Tourmaline Bio's outlook, capital allocation, and key risks for upcoming quarters, including guidance ranges or operating priorities where disclosed.

Tailwinds

  • Tourmaline Bio cites demand and execution supporting the near-term outlook.
  • Liquidity and balance-sheet capacity support operations and shareholder returns.

Headwinds

  • GAAP profitability remained under pressure in Q2 2025.
  • Macro, input costs, and FX may pressure margins quarter to quarter.
  • Segment mix and one-time items can affect comparability versus prior periods.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 6 quarterly earnings reports · overlaid with Q2 2025

Historical avgQ2 2025

+0.7%

Avg return

Earnings day

-5.0%

Avg return

5 days after

+13.7%

Avg return

30 days after

59%

10 / 17 earnings

Positive

+11.6%

Q4 2023

Best reaction

-9.7%

Q2 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025
Q2 2025+3.8%+3.1%+122.3%
Q1 2025+4.6%+9.9%+26.5%
Q4 2024-2.8%-4.8%-1.4%
Q3 2024+5.0%-4.9%-5.6%
Q2 2024+2.0%+4.6%+12.2%
Q1 2024-0.6%-4.8%+2.6%
Q4 2023+11.6%-38.1%-60.9%
Q3 2023-1.2%
Q2 2023+1.3%
Q1 2023-8.0%
Q4 2022+2.8%
Q3 2022+7.0%
Q2 2022-9.7%
Q1 2022+3.1%
Q4 2021+4.6%
Q3 2021-7.0%
Q2 2021-5.5%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro